For widespread eczema covering large body surface areas, systemic delivery (subcutaneous injection) ensures all affected areas receive benefit without the impracticality of applying topical preparations everywhere
Goldwaser: The biggest risk is the unknown
The dose-response data show a weight effect that flattens toward the top of the range alongside dose-dependent gastrointestinal adverse events, which is consistent with a tolerability-driven choice but that reading is an inference drawn here, not a documented rationale, and Novo Nordisk has published no dose-selection statement

Hypothetical Conservative Combination Protocol A conservative approach to combining these peptides would likely involve: Phase 1: Tirzepatide Establishment (Weeks 1-12) Week 1-4: Tirzepatide 2.5 mg weekly Week 5-8: Tirzepatide 5 mg weekly Week 9-12: Tirzepatide 7.5 mg weekly Cagrilintide: None (establish baseline tolerance) Phase 2: Cagrilintide Introduction (Weeks 13-20) Week 13-16: Tirzepatide 7.5 mg + Cagrilintide 0.6 mg weekly Week 17-20: Tirzepatide 7.5 mg + Cagrilintide 1.2 mg weekly Phase 3: Optimization (Week 21+) Tirzepatide 10-12.5 mg + Cagrilintide 2.4 mg weekly Adjust based on tolerance and response "The key principle when considering any peptide combination is sequential introduction with careful monitoring of tolerability markers, particularly gastrointestinal symptoms that could compound across mechanisms." This theoretical framework prioritizes safety through staged introduction, though actual clinical protocols would require medical supervision and monitoring

The compound helps grow strong tissue fibers and moves healing cells directly to the injury
Boost Your Energy with B12 Injections at Radiant A MedSpa